Mer­ck flesh­es out Keytru­da win in first-line cer­vi­cal can­cer, adding more fire­pow­er to its ear­ly can­cer push

Mer­ck has worked hard to bring its I/O block­buster Keytru­da in­to ear­li­er and ear­li­er lines of ther­a­py, and now the won­der drug ap­pears poised to make a quick en­try in­to ear­ly ad­vanced cer­vi­cal can­cer.

A com­bi­na­tion of Keytru­da and chemother­a­py with or with­out Roche’s Avastin cut the risk of death by 33% over chemo with or with­out Avastin (p=<0.001) in first-line pa­tients with per­sis­tent, re­cur­rent or metasta­t­ic cer­vi­cal can­cer, ac­cord­ing to full da­ta from the Phase III KEYNOTE-826 study pre­sent­ed Sat­ur­day at #ES­MO21.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.